| Eli Lilly and Company (LLY) | |||
|---|---|---|---|
| 733.655 -12.035 (-1.61%) | 04-24 13:04 | ||
| Open: | 752.64 | Pre. Close: | 745.69 |
| High: | 752.64 | Low: | 728.785 |
| Volume: | 1,060,060 | Market Cap: | 697,534(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 895.06 One year: 927.01 |
| Support: | Support1: 722.07 Support2: 600.76 |
| Resistance: | Resistance1: 766.32 Resistance2: 793.67 |
| Pivot: | 752.54 |
| Moving Averages: | MA(5): 735.97 MA(20): 757.24 MA(100): 692.25  MA(250): 583.74 |
| MACD: | MACD(12,26): -6.51 Signal(12,26,9): -2.50 |
| %K %D: | %K(14,3): 20.95 %D(3): 16.17 |
| RSI: | RSI(14): 40.39 |
| 52-Week: | High: 800.78 Low: 370.68 Change(%): 94.2 |
| Average Vol(K): | 3-Month: 3050 10-Days: 2200 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 746.764 - 749.635 | 749.635 - 752.934 |
| Low: | 723.592 - 726.689 | 726.689 - 730.248 |
| Close: | 739.874 - 744.894 | 744.894 - 750.664 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LLY ] has closed above bottom band by 15.3%. Bollinger Bands are 3.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 950.77 |
| Shares Float (M) | 897.84 |
| % Held by Insiders | 0.16 |
| % Held by Institutions | 84.34 |
| Shares Short (K) | 5420 |
| Shares Short Prior Month (K) | 5420 |
| Stock Financials | |
|---|---|
| EPS | 5.810 |
| Book Value (p.s.) | 11.980 |
| Profit Margin | 15.36 |
| Operating Margin | 34.14 |
| Return on Assets (ttm) | 11.9 |
| Return on Equity (ttm) | 48.4 |
| Qtrly Rev. Growth | 28.1 |
| Gross Profit (p.s.) | |
| Sales Per Share | 35.887 |
| EBITDA (p.s.) | 12.947 |
| Qtrly Earnings Growth | 13.00 |
| Operating Cash Flow (M) | 4240.00 |
| Levered Free Cash Flow (M) | 236.88 |
| Stock Valuation | |
|---|---|
| PE Ratio | 125.74 |
| PEG Ratio | 1.18 |
| Price to Book value | 60.98 |
| Price to Sales | 20.36 |
| Price to Cash Flow | 163.82 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
